Loading clinical trials...
Loading clinical trials...
A Prospective, Multicenter, Single-Arm Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies
Conditions
Interventions
Drugs and anti-CD19 CAR transduced T cells
Locations
5
China
Department of Hematology, Dongguan People's Hospital
Dongguan, Guangdong, China
Department of Hematology, the First People's Hospital of Foshan
Foshan, Guangdong, China
Department of Hematology, Guangzhou First People's Hospital
Guangzhou, Guangdong, China
Department of Hematology, The First Affiliated Hospital of Guangdong Pharmaceutical University
Guangzhou, Guangdong, China
Department of Hematology,the Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Start Date
June 30, 2017
Primary Completion Date
December 31, 2020
Completion Date
December 31, 2020
Last Updated
June 20, 2017
NCT05139017
NCT06263491
NCT05529069
NCT06337318
NCT07388563
NCT06189391
Lead Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions